181 related articles for article (PubMed ID: 35808895)
1. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K; Kaneda H; Osawa M; Izumi M; Yoshimoto N; Sugimoto A; Nagamine H; Ogawa K; Matsumoto Y; Sawa K; Tani Y; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Thorac Cancer; 2022 Aug; 13(16):2309-2317. PubMed ID: 35808895
[TBL] [Abstract][Full Text] [Related]
2. Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer.
Iso H; Hisakane K; Mikami E; Suzuki T; Matsuki S; Atsumi K; Nagata K; Seike M; Hirose T
Transl Lung Cancer Res; 2023 Sep; 12(9):1850-1861. PubMed ID: 37854151
[TBL] [Abstract][Full Text] [Related]
3. Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer.
Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Cancer; 2023 Aug; 129(15):2297-2307. PubMed ID: 37021822
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
7. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
8. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
9. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
10. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
11. Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
Yoneda T; Sone T; Koba H; Shibata K; Suzuki J; Tani M; Nishitsuji M; Nishi K; Kobayashi T; Shirasaki H; Araya T; Kita T; Kase K; Yamamura K; Terada N; Nishikawa S; Tambo Y; Kimura H; Kasahara K
Clin Lung Cancer; 2022 Sep; 23(6):467-476. PubMed ID: 35618628
[TBL] [Abstract][Full Text] [Related]
12. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.
Lin YY; Lin LY; Hang JF; Lin CH; Ho HL; Chou TY
Cancer Cytopathol; 2021 Feb; 129(2):148-155. PubMed ID: 32976705
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.
Galland L; Le Page AL; Lecuelle J; Bibeau F; Oulkhouir Y; Derangère V; Truntzer C; Ghiringhelli F
Oncoimmunology; 2021; 10(1):1957603. PubMed ID: 34377595
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Zhao Y; Mei T; Na F; Tian X; Ao R; Long X; Luo Q; Duan P; Zhu J; Wang Y; Huang M; Liu Y; Gong Y
Invest New Drugs; 2024 Apr; 42(2):196-206. PubMed ID: 38386170
[TBL] [Abstract][Full Text] [Related]
16. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
20. TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
Katayama Y; Yamada T; Morimoto K; Fujii H; Morita S; Tanimura K; Takeda T; Okada A; Shiotsu S; Chihara Y; Hiranuma O; Yamada T; Ota T; Harada T; Hasegawa I; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
JTO Clin Res Rep; 2023 Apr; 4(4):100494. PubMed ID: 37020925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]